Last reviewed · How we verify

BNT162b7 Bivalent (Original/OMI BA.4/BA.5) — Competitive Intelligence Brief

BNT162b7 Bivalent (Original/OMI BA.4/BA.5) (bnt162b7-bivalent-original-omi-ba-4-ba-5) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mRNA vaccine. Area: Infectious Disease.

marketed mRNA vaccine SARS-CoV-2 spike protein Infectious Disease Live · refreshed every 30 min

Target snapshot

BNT162b7 Bivalent (Original/OMI BA.4/BA.5) (bnt162b7-bivalent-original-omi-ba-4-ba-5) — Pfizer. BNT162b7 Bivalent is a mRNA-based vaccine targeting SARS-CoV-2 spike protein.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BNT162b7 Bivalent (Original/OMI BA.4/BA.5) TARGET bnt162b7-bivalent-original-omi-ba-4-ba-5 Pfizer marketed mRNA vaccine SARS-CoV-2 spike protein
protein subunit: Novavax COVID-19 vaccine protein subunit: Novavax COVID-19 vaccine Novavax marketed Protein subunit vaccine SARS-CoV-2 spike protein
BioNTech - Pfizer COVID-19 vaccine BioNTech - Pfizer COVID-19 vaccine University of Birmingham marketed mRNA vaccine SARS-CoV-2 spike protein (S protein)
Lilly Bamlanivimab + Etesevimab Lilly Bamlanivimab + Etesevimab Erin McCreary marketed Monoclonal antibody combination (neutralizing antibodies) SARS-CoV-2 spike protein receptor-binding domain
Comirnaty Original/Omicron BA.1 Comirnaty Original/Omicron BA.1 Jules Bordet Institute marketed mRNA vaccine SARS-CoV-2 spike protein (original strain and Omicron BA.1 variant)
batch 3 of Ad5-nCoV batch 3 of Ad5-nCoV Jiangsu Province Centers for Disease Control and Prevention marketed viral vector vaccine SARS-CoV-2 spike protein
Ad26.COV2.S vaccine Ad26.COV2.S vaccine University Medical Center Groningen marketed viral vector vaccine SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mRNA vaccine class)

  1. Pfizer · 12 drugs in this class
  2. ModernaTX, Inc. · 11 drugs in this class
  3. BioNTech SE · 5 drugs in this class
  4. Jules Bordet Institute · 5 drugs in this class
  5. Tan Tock Seng Hospital · 2 drugs in this class
  6. Clover Biopharmaceuticals AUS Pty · 1 drug in this class
  7. CanSino Biologics Inc. · 1 drug in this class
  8. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  9. CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 drug in this class
  10. Jens D Lundgren, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BNT162b7 Bivalent (Original/OMI BA.4/BA.5) — Competitive Intelligence Brief. https://druglandscape.com/ci/bnt162b7-bivalent-original-omi-ba-4-ba-5. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: